215 related articles for article (PubMed ID: 28973706)
1. Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.
Gangi A; Topham A; Lee MC; Sun W; Laronga C
South Med J; 2017 Oct; 110(10):649-653. PubMed ID: 28973706
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
3. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
4. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
[TBL] [Abstract][Full Text] [Related]
5. Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences.
Cutuli B; Wiezzane N; Palumbo I; Barbieri P; Guenzi M; Huscher A; Borghesi S; Delva C; Iannone T; Vianello E; Rosetto ME; Aristei C
Cancer Radiother; 2016 Jun; 20(4):292-8. PubMed ID: 27344537
[TBL] [Abstract][Full Text] [Related]
6. Controversies in the Treatment of Ductal Carcinoma in Situ.
Barrio AV; Van Zee KJ
Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E; Papadimitriou K; Tjalma W; Altintas S
Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
[TBL] [Abstract][Full Text] [Related]
8. Prescribing practices of endocrine therapy for ductal carcinoma
Chaudhry AT; Koulis TA; Speers C; Olson RA
Curr Oncol; 2018 Apr; 25(2):133-138. PubMed ID: 29719429
[TBL] [Abstract][Full Text] [Related]
9. Ductal carcinoma in situ, complexities and challenges.
Leonard GD; Swain SM
J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
Manders JB; Kuerer HM; Smith BD; McCluskey C; Farrar WB; Frazier TG; Li L; Leonard CE; Carter DL; Chawla S; Medeiros LE; Guenther JM; Castellini LE; Buchholz DJ; Mamounas EP; Wapnir IL; Horst KC; Chagpar A; Evans SB; Riker AI; Vali FS; Solin LJ; Jablon L; Recht A; Sharma R; Lu R; Sing AP; Hwang ES; White J;
Ann Surg Oncol; 2017 Mar; 24(3):660-668. PubMed ID: 27704370
[TBL] [Abstract][Full Text] [Related]
11. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.
Martínez-Pérez C; Turnbull AK; Ekatah GE; Arthur LM; Sims AH; Thomas JS; Dixon JM
Cancer Treat Rev; 2017 Apr; 55():163-172. PubMed ID: 28402908
[TBL] [Abstract][Full Text] [Related]
12. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
13. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
15. Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience.
Falco G; Rocco N; Procaccini E; Sommella MG; Bordoni D; Cenini E; Castagnetti F; Sabatino V; Compagna R; Della Corte GA; Accurso A; Amato B; Ferrari G
Int J Surg; 2014; 12 Suppl 2():S47-S49. PubMed ID: 25167849
[TBL] [Abstract][Full Text] [Related]
16. Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study.
Ozkaya Akagunduz O; Ergen A; Erpolat P; Gultekin M; Akkus Yildirim B; Parvizi M; Ikiz D; Colpan Oksuz D; Onal C; Yildiz F; Ozsaran Z
Breast; 2018 Dec; 42():10-14. PubMed ID: 30121548
[TBL] [Abstract][Full Text] [Related]
17. Contemporary treatment of ductal carcinoma in situ of the breast.
Mokbel K
Med Sci Monit; 2005 Mar; 11(3):RA86-93. PubMed ID: 15735580
[TBL] [Abstract][Full Text] [Related]
18. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.
Fish EB; Chapman JA; Miller NA; Link MA; Fishell E; Wright B; McCready DR; Hiraki GY; Ross TM; Hanna WM; Lickley HL
Ann Surg Oncol; 1998 Dec; 5(8):724-32. PubMed ID: 9869520
[TBL] [Abstract][Full Text] [Related]
19. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
20. Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis.
De Lorenzi F; Di Bella J; Maisonneuve P; Rotmensz N; Corso G; Orecchia R; Colleoni M; Mazzarol G; Rietjens M; Loschi P; Marcelli S; Veronesi P; Galimberti V
Eur J Surg Oncol; 2018 Jul; 44(7):957-962. PubMed ID: 29759643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
